

DESCRIPTION

Species Reactivity	Human/Mouse
Specificity	Detects human MEF2C in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human SRF is observed.
Source	Monoclonal Mouse IgG _{2B} Clone # 681824
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	<i>E. coli</i> -derived recombinant human MEF2C Ala135-Lys239 Accession # Q06413
Conjugate	Alexa Fluor 488 Excitation Wavelength: 488 nm Emission Wavelength: 515-545 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Immunocytochemistry	Optimal dilution of this antibody should be experimentally determined.
Immunohistochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

MEF2C (myocyte enhancer factor-2C) is a 51 kDa (predicted) protein that is one of four members of the MEF2/MADS (MCM1, Agamous, Deficiens, Serum response) box family of transcription factors. The 473 amino acid (aa) human MEF2C contains a MADS box for dimerization (aa 3-57), a DNA binding domain (aa 58-86), a beta domain (aa 271-278; missing in a 465 aa isoform), a transcriptional repressor (aa 368-399; missing in a 441 aa isoform) and several acetylation and ser/thr phosphorylation sites. Within aa 135-239, human MEF2C shares 95% and 98% aa identity with mouse and rat MEF2C, respectively. MEF2C plays important roles in preferential lymphoid differentiation of hematopoietic precursors, and in neuronal, cardiac and skeletal muscle morphogenesis.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.